Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.62 |
| ▸ | KIT | P10721 | 9/20 | 0.62 |
| ▸ | FLT3 | P36888 | 8/20 | 0.62 |
| ▸ | FLT1 | P17948 | 8/20 | 0.62 |
| ▸ | CSF1R | P07333 | 7/20 | 0.62 |
| ▸ | FLT4 | P35916 | 6/20 | 0.62 |
| ▸ | LCK | P06239 | 5/20 | 0.62 |
| ▸ | LYN | P07948 | 5/20 | 0.62 |
| ▸ | BLK | P51451 | 5/20 | 0.62 |
| ▸ | FYN | P06241 | 5/20 | 0.62 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | SRC | P12931 | 4/20 | 0.62 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | PLK4 | O00444 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703063 | 0.89 | KDR (0.77) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL2235613 | 0.89 | KDR (0.49) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL2239007 | 0.88 | KDR (0.48) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL2237860 | 0.86 | KDR (0.62) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL4912534 | 0.84 | KDR (0.44) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL14294640 | 0.81 | KDR (0.65) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL2238236 | 0.80 | KDR (0.64) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL12346395 | 0.79 | KDR (0.63) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL2235077 | 0.78 | KDR (0.61) | KDRKITFLT3FLT1CSF1R | |
| SCHEMBL2237544 | 0.77 | KDR (0.60) | KDRKITFLT3FLT1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | claimed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| CN-101146534-A | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA SA (FR) | 2008-03-19 | — | — | CN | claimed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | claimed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | claimed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | claimed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| CN-101146534-A | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA SA (FR) | 2008-03-19 | — | — | CN | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885KIT 358/4885FLT3 121/4885 |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885KIT 358/4885FLT3 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.